IDEXX Laboratories, Inc. (NASDAQ:IDXX) Shares Acquired by Impax Asset Management Group plc

Impax Asset Management Group plc boosted its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 14.7% during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 8,655 shares of the company’s stock after acquiring an additional 1,110 shares during the period. Impax Asset Management Group plc’s holdings in IDEXX Laboratories were worth $4,373,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Crewe Advisors LLC bought a new position in shares of IDEXX Laboratories during the first quarter worth about $26,000. Ridgewood Investments LLC acquired a new position in shares of IDEXX Laboratories during the second quarter valued at $27,000. Institutional & Family Asset Management LLC acquired a new position in shares of IDEXX Laboratories during the second quarter valued at $28,000. E Fund Management Hong Kong Co. Ltd. increased its holdings in shares of IDEXX Laboratories by 5,700.0% during the third quarter. E Fund Management Hong Kong Co. Ltd. now owns 58 shares of the company’s stock valued at $29,000 after purchasing an additional 57 shares during the period. Finally, Mowery & Schoenfeld Wealth Management LLC increased its holdings in shares of IDEXX Laboratories by 750.0% during the third quarter. Mowery & Schoenfeld Wealth Management LLC now owns 68 shares of the company’s stock valued at $34,000 after purchasing an additional 60 shares during the period. 87.84% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on the company. Barclays lowered their price target on IDEXX Laboratories from $570.00 to $481.00 and set an “overweight” rating on the stock in a report on Monday, November 4th. Stifel Nicolaus lowered their price target on IDEXX Laboratories from $510.00 to $500.00 and set a “hold” rating on the stock in a report on Thursday, October 10th. Piper Sandler reaffirmed a “neutral” rating and set a $435.00 target price (down previously from $520.00) on shares of IDEXX Laboratories in a research note on Monday, November 4th. BTIG Research assumed coverage on IDEXX Laboratories in a research note on Thursday, July 25th. They set a “buy” rating and a $580.00 target price for the company. Finally, JPMorgan Chase & Co. decreased their target price on IDEXX Laboratories from $630.00 to $575.00 and set an “overweight” rating for the company in a research note on Friday, October 11th. Three equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $552.38.

IDEXX Laboratories Trading Down 0.6 %

NASDAQ:IDXX opened at $420.91 on Friday. The company has a quick ratio of 1.03, a current ratio of 1.42 and a debt-to-equity ratio of 0.32. IDEXX Laboratories, Inc. has a 1-year low of $404.74 and a 1-year high of $583.39. The firm has a market capitalization of $34.47 billion, a price-to-earnings ratio of 40.59, a price-to-earnings-growth ratio of 3.75 and a beta of 1.36. The stock has a fifty day simple moving average of $469.35 and a 200 day simple moving average of $483.39.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings results on Thursday, October 31st. The company reported $2.80 earnings per share for the quarter, beating analysts’ consensus estimates of $2.69 by $0.11. IDEXX Laboratories had a return on equity of 55.42% and a net margin of 22.53%. The business had revenue of $975.50 million during the quarter, compared to analyst estimates of $980.32 million. During the same quarter last year, the company posted $2.53 EPS. IDEXX Laboratories’s revenue for the quarter was up 6.6% on a year-over-year basis. Sell-side analysts forecast that IDEXX Laboratories, Inc. will post 10.43 earnings per share for the current year.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.